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Abstract
Background: Mortality from colorectal cancer is mainly due to metastatic liver disease. Improved
understanding of the molecular events underlying metastasis is crucial for the development of new
methods for early detection and treatment of colorectal cancer. Loss of chromosome 8p is
frequently seen in colorectal cancer and implicated in later stage disease and metastasis, although
a single metastasis suppressor gene has yet to be identified. We therefore examined 8p for genes
involved in colorectal cancer progression.
Methods: Loss of heterozygosity analyses were used to map genetic loss in colorectal liver
metastases. Candidate genes in the region of loss were investigated in clinical samples from 44
patients, including 6 with matched colon normal, colon tumour and liver metastasis. We
investigated gene disruption at the level of DNA, mRNA and protein using a combination of
mutation, semi-quantitative real-time PCR, western blotting and immunohistochemical analyses.
Results: We mapped a 2 Mb region of 8p21-22 with loss of heterozygosity in 73% of samples; 8/
11 liver metastasis samples had loss which was not present in the corresponding matched primary
colon tumour. 13 candidate genes were identified for further analysis. Both up and down-regulation
of 8p21-22 gene expression was associated with metastasis. ADAMDEC1 mRNA and protein
expression decreased during both tumourigenesis and tumour progression. Increased STC1 and
LOXL2 mRNA expression occurred during tumourigenesis. Liver metastases with low DcR1/
TNFRSF10C mRNA expression were more likely to present with extrahepatic metastases (p =
0.005). A novel germline truncating mutation of DR5/TNFRSF10B  was identified, and DR4/
TNFRSF10A SNP rs4872077 was associated with the development of liver metastases (p = 0.02).
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Conclusion: Our data confirm that genes on 8p21-22 are dysregulated during colorectal cancer
progression. Interestingly, however, instead of harbouring a single candidate colorectal metastasis
suppressor 8p21-22 appears to be a hot-spot for tumour progression, encoding at least 13 genes
with a putative role in carcinoma development. Thus, we propose that this region of 8p comprises
a metastatic susceptibility locus involved in tumour progression whose disruption increases
metastatic potential.
Background
Mortality from colorectal cancer (CRC), the fourth most
frequent cause of cancer deaths, is mainly due to meta-
static liver disease. Much is known about the adenoma-
carcinoma progression of CRC [1-3] and sporadic CRC is
recognised as a heterogeneous and complex disease
involving many genes and pathways [4,5]. There has been
intensive analysis of the prognostic value of molecular
markers for CRC in risk assessment and disease manage-
ment [6-11]. Despite intense study of the metastatic proc-
ess many aspects of its molecular genetic basis remain
unclear. Improved understanding of the molecular events
underlying metastasis is crucial for the development of
new methods for early detection and treatment of colorec-
tal cancer.
Traditionally, loss of heterozygosity (LOH) analyses were
used to map regions harbouring tumour suppressor
genes; this method exploits Knudson's two hit hypothesis
of tumorigenesis [12] We reasoned that LOH analyses
could be used to map chromosomal regions specifically
disrupted in metastases, and might therefore highlight the
presence of a gene(s) involved in metastasis.
Chromosome 8p is frequently lost in CRC, many studies
implicate loss in later stage disease and metastases [13-
15], and several 8p genes have been implicated in metas-
tasis [16-19]. However, to date no strong candidate CRC
metastasis suppressor has been identified showing loss of
expression and/or function in a significant proportion of
tumours, as compared to the frequent mutation and/or
silencing of genes involved in adenoma-carcinoma pro-
gression [20]. We therefore concentrated our analysis on
8p, identified a region of metastasis-specific loss, and
screened genes within this region for changes at the DNA,
mRNA and/or protein level associated with metastasis.
Methods
Samples
48 sporadic CRC patients undergoing surgery at Wakefield
Gastroenterology Centre for primary colon and/or sec-
ondary liver tumour resection were included, along with
20 patients with sporadic CRC and no liver metastases
(follow-up 2.5–8.5 years, Mean 5.1 +/- 1.9). Matched pri-
mary colon tumour and liver metastasis samples were
available for 11 patients. Informed, written consent was
obtained from each patient. The Central Regional Ethics
Committee approved the study (CEN/05/02/004), which
complied with the Helsinki Declaration for human
research. Immediately post-surgery tumour samples were
dissected macroscopically to remove non-tumour tissue,
snap-frozen and stored at -80°C. Blood samples were
obtained for all patients.
Nucleic acid extraction
Tumour DNA and RNA were extracted with Qiagen
(Valencia, CA, USA) DNA Purification kit and Trizol rea-
gent (Invitrogen Corp, Carlsbad, CA USA) respectively.
Blood DNA was extracted using the Qiagen DNA Blood
kit.
Microsatellite markers and PCR
35 microsatellite markers, spanning 8p21-22 and part of
8q (D8S277, D8S1819, D8S351, D8S 721, D8S542,
D8S520, D8S1759, D8S552, D8S1754, D8S511,
D8S1827, D8S1731, D8S254, D8S261, D8S258, LPL,
D8S136, D8S1786, D8S1752, D8S1734, D8S1181,
D8S360, NEFL, D8S1725, D8S1739, D8S1048, D8S1809,
D8S283, D8S513, D8S505, D8S325, D8S1821, D8S1745,
D8S1773, D8S1833) were used. PCR used: 20 ng DNA 50
pmol each primer, 200 μM dNTPs, 1.5 mM MgCl2, and
0.15 units FastStart Taq (Roche Applied Science, Indiana-
polis, IN, US) in 50 μl volume. Cycling conditions were: 1
cycle 95°C 10 min, 30 cycles 95°C 30s 55 or 60°C 30s
72°C 30s, and 1 cycle 72°C 8 min.
Loss of heterozygosity
As previously [21,22]. Briefly, 5 μl PCR product was dena-
tured prior to electrophoresis and DNA visualized by sil-
ver staining. Scoring was carried out independently by 2
scientists, and a 3rd scientist independently reviewed all
results
cDNA synthesis and semi-quantitative real-time PCR
500 ng of RNA was reverse transcribed using random hex-
amers and Superscript III (Invitrogen) as per the manufac-
turer. To identify a robust internal control an ABI Human
Endogenous Control Plate was run against 4 paired nor-
mal colon (CN) and colon tumour (CT) samples. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase), acidic
ribosomal protein and 18s were selected for further vali-
dation in CN, CT and liver metastases (LM). All 3 showedBMC Cancer 2008, 8:187 http://www.biomedcentral.com/1471-2407/8/187
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minimal variation between and among tissues (data not
shown). TaqMan quantitative real-time PCR was per-
formed using ABI (Applied Biosystems Foster City, CA,
USA) reagents and assay on demands (Additional file 1)
as per the manufacturer. Amplification efficiency and
primer interference were checked using standard curves.
Samples were run and analysed in triplicate on an ABI
7300 or 7700. Test gene expression was normalised to 18s
(dCt). Fold change (FC) of CT or LM gene expression was
calculated relative to matched normal using mean dCt
values and FC = 2-ddCt. KRT8 was used as an epithelial cell-
specific marker [23].
Mutational analysis
PCR used: 10 ng DNA, 400 μM primer (Additional file 2),
200 μM dNTPs, 2.0 mM MgCl2, and 0.8 units FastStart
Taq (Roche) in 30 μl, and cycling conditions: 1 cycle 95°C
4 min, and 38 cycles of 94°C 30s annealing (supplemen-
tary information) 20s 72°C 60s. DR5 (NM_003842) was
amplified from cDNA as 2 over-lapping amplicons. An
aliquot of each PCR product was checked before clean-up
(Qiagen PCR purification columns) by agarose gel electro-
phoresis, sequencing was performed in both directions
and anomalies verified by repeat analysis. Restriction
analyses of DR4 were as previously described [24,25].
Immunohistochemistry (IHC)
Immunohistochemistry was undertaken on formalin-
fixed paraffin-embedded (FFPE) archival material. Mouse
or rabbit Vectastain ABC Peroxidase Kit and Vecta Red Per-
oxidase substrate kits (Vector Laboratories, Burlingame,
CA, USA) were used according to the manufacturer and
sections counterstained with haemotoxylin. DR5
(Imgenex Corp, San Diego, CA, USA clone 45B872.1) and
PDLIM2 [26] antibodies were incubated for 1 h at 37°C
and used at 1:1000 and 1:500 respectively.
Western blot
Frozen cryosections were extracted in cell lysis buffer.
Tumour tissue contained >95% pure tumour as deter-
mined by haematoxylin and eosin staining of every fifth
section. Samples were resolved by SDS-PAGE, transferred
to nitrocellulose membrane and probed with antibodies
against DR5 (1:10 000 Imgenex, clone 45B872.1),
GAPDH (1:20 000 Imgenex, clone IMG-5019A-1) or
ADAMDEC1 (1:600 Abnova, Taipei City, Taiwan, Clone
64C). Signals were developed using SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce Biotechnol-
ogy, Rockford, IL, USA).
Statistical analyses
Statistical analysis of polymorphism frequency and hap-
lotype (LD) data involved the use of contingency tables.
The strength and probability of association were meas-
ured using the R-squared statistic and chi-squared distri-
bution respectively. Comparison of mean Ct values in
real-time gene expression analyses was assessed using the
independent samples T-test. An alpha level of 0.05 was set
as the significance threshold.
Results
Identification of metastasis-specific LOH at 8p21-22
LOH analysis of the entire length of chromosome 8p in
matched CT (colon tumour) and LM (liver metastases)
identified loss in 8/11 cases; of these, 6/8 showed regions
of metastasis-specific LOH (MSL) (Figure 1a). One com-
mon region of MSL (NEFL (neurofilament protein, light
polypeptide) to D8S1786) was selected for analysis in a
further 36 LMs. LOH analysis of 8p21-22 in LMs revealed
loss of at least one informative marker in 69% of cases
(33/48) compared to matched blood. Of these 33, 15
showed loss at every informative marker analysed, sug-
gesting loss of the entire arm of 8p (45%). 18 LMs showed
discreet regions of loss (Figure 1b), and samples from one
patient (#22) allowed identification of a minimal region
of loss, between markers D8S1734-NEFL (2019 kb) (Fig-
ure 1c).
Mutational analysis of candidate genes
Examination of the published DNA sequence [27]
revealed that the minimal region of MSL harboured the
tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL) Receptor (TRAILR) gene cluster and a number of
other candidates (Figure 2). TRAILR DR5 has been impli-
cated in metastasis [19,28]. Another strong candidate,
PDLIM2, is reported to promote cell attachment and
migration and suppress anchorage-independent growth
[26] and is involved in inactivation of NF-kappaB [29].
Therefore, we targeted TRAILRs DR5 and DR4, and
PDLIM2 for mutational analyses. Of the 48 LM DNA sam-
ples used for LOH analysis, 44 had sufficient sample for
mutational analyses and RNA was available for 34/44.
Germline termination mutation in DR5
As no particular hot-spots for mutation had previously
been identified in DR5 we decided to screen the entire
protein-coding region by sequencing 2 over-lapping
amplicons from cDNA. Although this technique would
miss any intronic splice site mutations we reasoned that it
allowed a comprehensive screen for any coding mutations
and that at least some splice variants might be identified
as alternative amplicons. This analysis revealed known
polymorphisms T95C, C200T and C572T (Table 1). A
C790T transition (numbering [30]) in exon 7 was identi-
fied in one patient. C790T was predicted to introduce a
premature stop codon (CGA to TGA, aa264) resulting in a
truncated DR5 protein (28 kDa vs 47 kDa as primary
amino acid sequence) devoid of the death domain.
Sequencing of blood and LM revealed the patient as a
germline heterozygote (Figure 3a) and suggested loss ofBMC Cancer 2008, 8:187 http://www.biomedcentral.com/1471-2407/8/187
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the wild type allele in the LM. LM tissue was available for
protein extraction for the C790T individual. This detected
a protein band of approximately 28 kDa which corre-
sponds to the predicted size of the truncated DR5 and
failed to detect a band corresponding to the wild-type pro-
tein, further suggesting the possibility of loss of the wild-
type allele in the LM for this patient. (Figure 3b). Matched
CN, CT and LM archival samples were available for immu-
nohistochemistry. More than 95% of cancer cells in the
wild-type CT and LM and in the C790T CT were positive
for DR5. However, approximately only 50% of cells were
positive for DR5 in the C790T LM by immunostaining
(Figure 3c). The highly DR5 positive cells were concen-
trated at the luminal surface in CN and at the invasive
Minimal region of LOH in CRC liver metastases Figure 1
Minimal region of LOH in CRC liver metastases. a. 21 markers between D8S351-D8S1745 on chromosome 8 in 
matched colon tumour (CT) and liver metastases (LM) for 6 patients. Markers are ordered and oriented with telomeric end 
top centromeric end bottom. LOH (open circle), retention (closed circle) and Non-informative (line) are indicated. The boxed 
region indicates markers selected for analysis of larger series of LM samples results shown in Figure 1b. b. Selected markers 
D8S1786-NEFL on 8p21 in LM for 21 patients. Markers are ordered and oriented with telomeric end top centromeric end 
bottom. LOH (open circle), retention (closed circle) and Non-informative (line) are indicated. The boxed region highlights the 
minimal region of loss identified in patient #22. c. Loss of microsatellite marker D8S1181 (arrow) defining the minimal region 
of loss in patient #22. Retention of markers D8S1734, NEFL and D8S1048 and loss of D8S1181 in tumour (LM liver metas-
tases) compared to normal (B, blood) are shown.d. Metastasis Specific Loss at D8S1181. Gel images illustrating loss (arrow) of 
D8S1811 in liver metastases (LM) but not matched normal (B, blood) or colon tumour (CT) in 2 patients.
Schematic representation of human chromosome 8p showing the minimal region of metastasis-specific loss (MSL) Figure 2
Schematic representation of human chromosome 8p showing the minimal region of metastasis-specific loss 
(MSL). The position of microsatellite markers and the relative location and orientation of the 13 genes investigated are 
shown. A total of 25 protein-coding genes are located in this region (see additional information).BMC Cancer 2008, 8:187 http://www.biomedcentral.com/1471-2407/8/187
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front of the CT tissues as previously reported [31]. The
DR5 positive cells in the C790T LM, some of which had a
high level of expression, were morphologically distinct
and poorly differentiated (Figure 3c).
Novel DR4 polymorphism in metastasising CRC
We targeted the cysteine-rich extracellular ligand binding
domain (exons 3, 4 and 5), and intracellular death
domain (exon 9). DNA sequencing and confirmatory
restriction analysis detected known polymorphisms
G422A, C626G, and A683 (Table 1).
The G allele of SNP (single nucleotide polymorphism)
rs4872077 was significantly more frequent in individuals
with LM (27/44, 6 homozygous G, 21 heterozygotes) than
those without (6/20, all heterozygous) p = 0.02.
rs4872077 was in linkage disequilibrium with two DR4
polymorphisms G422A and C626G (r2 = 0.50 and 0.48
respectively, p = 0.001) previously shown to co-segregate
[24]; in our study the linkage disequilibrium between
G422A and C626G was r2 = 0.914, p < 3 × 10-17.
Novel polymorphism in PDLIM2
We targeted the PDZ and LIM domains which have roles
in the assembly of protein complexes (PDZ, [32]) and act
as protein binding interfaces found in transcription fac-
tors, kinases and scaffolding proteins (LIM, [33]). The two
domains span several exons and were amplified inde-
pendently from cDNA. A novel, heterozygote C to T tran-
sition at nt1281 (NM_021630) was detected (3/34). All
three were heterozygous for C1281T in germline DNA
(data not shown).
Gene expression analysis for CRC metastasis
Mutation is one mechanism of gene disruption. To pro-
vide a general screen at the transcriptional level we
extended our search to a semi-quantitative real-time PCR
analysis of DR5, DR4, PDLIM2 and a further 10 potential
Table 1: Frequency of Polymorphisms in Liver Metastases 
Samples
Polymorphism Frequency
DR4 G422A Exon1 35/44
DR4 C626G Exon 2 35/44
DR4 A683C Exon 5 13/44
DR4 A+12Ex5G Intronic 27/44
DR4 A1322G DD Exon 9 7/44
DR5 T95C Exon 1 22/34
DR5 C200T Exon 2 3/34
DR5 C572T Exon 5 6/34
PDLIM2 C1281T Exon 9 3/44
DNA, Western and Immunohistochemical analysis of the TRAIL DR5 C790T mutation Figure 3
DNA, Western and Immunohistochemical analysis of the TRAIL DR5 C790T mutation. a Chromotagrams showing 
DR5 C790T in blood, and liver metastases DNA and cDNA. F & R indicate forward and reverse primers respectively, the arrow 
indicates C790T. b. Western Blot of DR5 for both a wild-type DR5 and the C790T LM. c. Immunohistochemistry for DR5 in 
matched colon normal (CN), the invasive front (*) of the primary colon tumour (IF), the central region of the primary tumour 
(CT) and liver metastasis (LM) from GAPDH is shown as a loading control. c both wild-type DR5 and C790T individuals.BMC Cancer 2008, 8:187 http://www.biomedcentral.com/1471-2407/8/187
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mRNA gene expression analyses for 13 genes Figure 4
mRNA gene expression analyses for 13 genes. a. Fold change gene expression in colon tumour (black) and liver metas-
tases (white) relative to colon normal. Gene expression was expressed as the change in Ct of the gene of interest compared to 
the 18s control (dCt) and relative expression calculated using the comparative CT method with fold change (2-ddCt). Fold 
change is shown on a logarithmic scale. b. Fold change gene expression of colorectal tumours (black) and liver metastases 
(white) relative to the matched colon normal. Fold change is presented on a logarithmic scale and was calculated as above.
candidates (Figure 2). The 2 Mb region of MSL harbours
25 protein-coding genes ([27] and Additional file 3). At
the time of study we picked the next 10 best candidates
based on a literature search and sequence alignments
(DNA & protein) to reveal any pertinent homologies or
potential functions. These were: the TRAIL decoy recep-
tors DcR1 and DcR2; DBC1 which is homozygously
deleted in breast cancers [34], and has a role in apoptosis
[35,36]; DBC2 a RhoGTPase and putative breast tumour
suppressor gene [34] implicated in apoptosis, cell cycle
control, cytoskeleton and membrane trafficking [37,38]
and down-regulation of Cyclin D1 [39]; STC1 which is
induced by BRCA1 and VEGF and up-regulation is
reported in a number of cancers [4,40]; LOXL2 which is
differentially expressed in various tumours [41-43] and
interacts with SNAIL [44,45]; CHMP7 which may func-
tion in endosomal sorting [46]; NKX3.1 a prostate tumour
suppressor [47,48], and two members of the ADAM (a
disintegrin and metalloproteinase) family (ADAM28 and
ADAMDEC1) whose members play a role in carcinoma
progression[49].
mRNA levels were investigated in 34 LM samples and 14
matching CT samples. 6 colon normal (CN) samples with
matching LM and CT (as above) were also analysed. Mean
expression data for the 13 genes across the 3 tissues was
calculated (Additional file 4) and mean fold change
expression in colon tumour and liver metastases relative
to colon normal is presented in Figure 4a.BMC Cancer 2008, 8:187 http://www.biomedcentral.com/1471-2407/8/187
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ADAMDEC1
A striking decrease in ADAMDEC1 mRNA expression was
observed in CT compared with paired CN; expression
decreased further in matched LM (Figure 4b). Data from
the NCBI Geo profile [50] supports this observation. Var-
ying levels of ADAMDEC1 mRNA have been detected in
normal human colon (GDS2062, GDS829, GDS1096,
GDS559, and original publication [51]). Two studies
(GDS2062 and GDS829) included normal colon and
colon adenocarcinoma cell lines, SW480 or CaCo2, and
expression was detected in normal tissue with very low or
undetectable levels in the cell lines. ADAMDEC1 protein
expression was detected in 12/20 normal adjacent colon
samples by Western Blot (data not shown). Western anal-
ysis of ADAMDEC1 expression in 13 matched CT and LM
samples (3 with matching CN) detected protein in 2/3CN,
5/13 CT and 0/13 LM samples (representative western
shown in Figure 5).
Six patients had a family history of CRC (first and/or sec-
ond degree relatives). ADAMDEC1 mRNA expression was
decreased to a lesser extent in the LM samples of these
patients relative to those with no family history (4-fold
difference in expression, T-test p = 0.02).
PDLIM2
A decrease in mRNA expression was observed for PDLIM2
in 5/6 CT samples compared with matched CN (Figure
4b). Immunohistochemistry did not reveal any difference
in the level or location of protein expression between
matched CT and LM (Additional file 5).
STC1 & LOXL2
We observed increased mRNA expression for STC1 and
LOXL2 in tumour tissue (Figure 4b), consistent with pre-
vious reports [4,40,41,43].
DcR1
Relationships between gene expression (all 13 genes) and
clinical outcome were investigated using clinical parame-
ters of survival: development of extra hepatic disease post-
LM resection; 3 year survival; histological grade of the CT,
and presence of metachronous or synchronous metas-
tases. A 2.5 fold lower mRNA expression of DcR1 in LM
samples was associated with an increased likelihood of
extra hepatic disease at 12 months post liver tumour resec-
tion. (T-test p = 0.005, n = 30. Data not shown). In CT
samples there was a trend towards this association (T-test
p = 0.051, n = 14, fold change of 2.4).
Discussion
Disruption of 8p is common in many cancers and could
simply indicate the relative instability of this region such
that disruption is a consequence of disease rather than
playing a causative role in tumour progression. In CRC 8p
loss has been implicated in later stage disease and metas-
tasis [13-15] and this study again highlights 8p identifying
a 2 Mb region of metastasis-specific loss at 8p21-22. In
addition, there is compelling evidence for the role of sev-
eral 8p genes in carcinogenesis, including a number stud-
ied here, such as the prostate tumour suppressor NKX3.1,
TRAILR DR5, DBC2 and STC1. This tends to argue against
8p disruption being primarily a consequence of tumouri-
genesis.
Western analysis of ADAMDEC1 Figure 5
Western analysis of ADAMDEC1. Analysis of matched CN (colon normal), CT (colon tumour) and LM (liver metastasis) 
for 13 patients is shown. GAPDH was used as a loading control. Numbers refer to patients IDs and allow cross-referencing to 
LOH and gene expression data where appropriate. Letters correspond to additional samples for whom mRNA expression and 
LOH was not undertaken. Where available mRNA expression is shown as mean dCt (Y-axis) underneath the corresponding 
sample and Fold Change for LM relative to CT is presented.BMC Cancer 2008, 8:187 http://www.biomedcentral.com/1471-2407/8/187
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In this study the most promising candidate at the mRNA
level was ADAMDEC1. We observed decreased mRNA
expression in CT and LM compared to CN (Figure 4b). No
detectable protein was expressed in 13 LM, and in 3/13
matched CT samples ADAMDEC1 was detected which
adds weight to the possibility that loss of expression is
progressive through tumourigenesis and may play a role
in metastasis. (Figure 5). ADAM family members are
involved in cancer progression[49] adding further support
to the possibility that this unique family member also has
a role in tumourigenesis.
We also identified a germline mutation of DR5 which may
provide additional insights into the function of this
TRAILR. C790T truncates DR5 (Figure 3b) resulting in a
protein devoid of the death domain and a potential func-
tional similarity to DcR2. Several studies have also identi-
fied truncating mutations of DR5 located prior to the
death domain [52-55]. One (another germline mutation)
showed loss of the growth suppressive function of wild-
type DR5 in HNSCC (head and neck squamous cell carci-
noma), ovarian and CRC cell lines [53]. Despite the diag-
nosis of synchronous liver metastases the C790T patient
did not develop extra-hepatic metastases, responded well
to hepatic chemotherapy (5-flurouracil (5-FU)) and SIRT
(selective internal radiation) and had > 5-year survival
post LM diagnosis. Inducible loss of DR5 protein expres-
sion promotes the growth of colon tumours in mice and
confers resistance to 5-FU, without causing resistance to
TRAIL-induced apoptosis [56]. This is in contrast to the
clinical observations for the C790T patient (slow tumour
growth and p53-responsiveness to 5FU and SIRT).
The heterogeneous or "patchy" C790T DR5 immunos-
taining and lack of a wild-type DR5 in C790T LM by west-
ern analysis suggests complete loss of the wild-type DR5
in C790T LM. The clinical data indicate that the C790T
DR5 may have a dominant negative effect, similar to
DcR2, including retention of the ability to respond to
p53-dependent therapy, and prevention of controlled
proliferation, in contrast to null DR5 experimental mod-
els [56].
In light of the wealth of evidence implicating 8p in CRC
progression it is perhaps surprising that no strong candi-
date tumour and/or metastatic suppressor has been iden-
tified. Other possibilities are that the 'candidate(s)' could
be a microRNA or other non-coding RNA or that haploin-
sufficiency (rather than gene 'knock-out') is sufficient for
tumourigenesis. Alternatively, a single gene/RNA may not
be the main 'effector' but rather it could be a combinato-
rial effect whereby a number of genes are involved and
perturbation of them all, or a subset thereof, results in
tumour progression.
The 2 Mb region in this study certainly appears to be a hot-
spot for genes involved in carcinogenesis, and contains 3
gene clusters, TRAILR, ADAM and NKX3.1/NKX2.6, each
encoding members with a role in tumour progression.
There is evidence for the clustering of co-expressed genes
in eukaryotes [57], as well as increasing recognition that
dynamic chromosomal architecture and genomic reposi-
tioning play an important role in gene regulation [58]. An
indication that clustering is of functional importance at
8p21-22 is suggested by the observation of co-regulation
at the mRNA transcriptional level and co-methylation pat-
terns for the TRAILR pairs DcR1 and DcR2 and DR4 and
DR5 in neuroblastoma cell lines [59]. We performed Pear-
sons' correlation analysis on the gene expression data for
the 13 candidate genes in both CT and LM. This revealed
potential transcriptional relationships between a number
of genes including DR4 and DR5 (Additional file 6) which
adds support to the possibility that the clustering of
'tumour' genes within this region is of functional signifi-
cance.
In addition, this possibility is further supported by recent
evidence demonstrating that the nuclear protein SATB1
acts as a 'genomic organiser' involved in the epigenetic
remodelling of chromatin to facilitate upregulation of
metastasis-associated genes and down-regulation of
tumour suppressors [60]. Although the genes investigated
by Han et al were not clustered, 8p21-22 may be a key can-
didate target of such regulation, the clustering providing a
further mechanism for co-ordinated control.
Metastasis might be viewed as a complex disorder in
which genetic and environmental factors interact, subtle
modulations of cellular activity being required to facilitate
survival. We propose that 8p21-22 may not contain a CRC
metasatasis suppressor(s) and that the clustering of a large
number of genes in one region under co-ordinated con-
trol bears closer resemblance to a complex disease,
whereby the overall combined profile of multiple genes
contributes to the phenotype.
Conclusion
This study identified a metastatic susceptibility locus
within a 2 Mb region of 8p21-22, which appears to be a
"hot-spot" for genes with a role in carcinoma develop-
ment and revealed ADAMDEC1 as a potential tumour
suppressor. We suggest that the rich nature of this region
for genes with a role in tumour development is of patho-
logical significance such that the genes may form a cluster
disruption of which favours CRC tumour progression. The
possibility of relationships between the genes is sup-
ported by the presence of several gene clusters, our obser-
vation of potential transcriptional associations, and van
Noesels et al observation of transcriptional co-regulation
and co-methylation of the DR4/DR5 and DcR1/DcR2BMC Cancer 2008, 8:187 http://www.biomedcentral.com/1471-2407/8/187
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TRAILR pairs [59]. As understanding of the role of
genomic architecture increases it may become essential to
consider neighbouring genes (in genomic and/or nuclear
space) to fully understand both gene function and carci-
noma progression.
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